{"prompt": "['CONFIDENTIAL', 'Verrica Pharmaceuticals Inc.', 'VP-102', 'Clinical Protocol: VP-102-103', 'TABLE OF CONTENTS', 'Page', 'LIST OF TABLES', '15', 'LIST OF FIGURES', '15', 'LIST OF ABBREVIATIONS', '16', '1.0', 'INTRODUCTION', '17', '1.1', 'MOLLUSCUM CONTAGIOSUM', '17', '1.2', 'CANTHARIDIN', '17', '1.2.1', 'Nonclinical Studies with Cantharidin', '19', '1.2.2', 'Clinical Studies with Cantharidin', '20', '1.3', 'STUDY RATIONALE', '23', '1.4', 'DOSE RATIONALE', '24', '1.5', 'PRIMARY OBJECTIVE', '25', '1.6', 'SECONDARY OBJECTIVES', '25', '2.0', 'STUDY DESIGN', '25', '2.1', 'BASIC DESIGN CHARACTERISTICS', '25', '2.2', 'STUDY POPULATION', '27', '2.2.1', 'Inclusion Criteria', '27', '2.2.2', 'Exclusion Criteria', '29', '2.3', 'ENDPOINTS', '30', '2.3.1', 'Safety', '31', '2.3.2', 'Efficacy', '32', '2.4', 'REPLACEMENT OF DROPOUTS', '32', '3.0', 'DRUGS AND DOSAGES', '33', '3.1', 'IDENTIFICATION AND DESCRIPTION OF INVESTIGATIONAL PRODUCT', '33', '3.1.1', 'Investigational Product', '33', '3.1.2', 'Labeling', '34', '3.2', 'DOSING INSTRUCTIONS AND SCHEDULE', '36', '3.3', 'STORAGE AND HANDLING OF INVESTIGATIONAL PRODUCT', '37', '3.4', 'CONCOMITANT MEDICATIONS', '38', '4.0', 'EXPERIMENTAL PROCEDURES', '39', '4.1', 'OVERVIEW: SCHEDULE OF TIME AND EVENTS', '39', '4.2', 'MEASUREMENTS AND EVALUATIONS', '41', '4.2.1', 'Screening Period (Up to 14 days prior to Day 1 visit or on Day 1 visit)', '41', '4.2.2', 'Evaluations (Treatment Day 1)', '42', '4.2.3', 'Evaluations: (Treatments Day 21, 42 and 63)', '43', '4.2.4', 'Evaluation Period / End of Study (~Day 84 or earlier if patient is completely clear', 'of molluscum):', '44', '5.0', 'PROCEDURES FOR HANDLING ADVERSE EVENTS AND SERIOUS ADVERSE', 'EVENTS', '46', 'Page 12']['CONFIDENTIAL', 'Verrica Pharmaceuticals Inc.', 'VP-102', 'Clinical Protocol: VP-102-103', 'TABLE OF CONTENTS (continued)', 'Page', '5.1', 'DEFINITION OF AN ADVERSE EVENT', '46', '5.2', 'DEFINITION OF A SERIOUS ADVERSE EVENT', '48', '5.3', 'RECORDING ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS', '49', '5.4', 'ASSESSMENT OF INTENSITY', '50', '5.5', 'ASSESSMENT OF CAUSALITY', '50', '5.6', 'EXPECTEDNESS OF SERIOUS ADVERSE EVENTS', '51', '5.7', 'REPORTING OF SERIOUS ADVERSE EVENTS', '52', '5.8', 'FOLLOW-UP OF ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS', '53', '5.9', 'PREGNANCY', '53', '6.0', 'STUDY OR SITE TERMINATION AND SUBJECT DISCONTINUATION', '54', '6.1', 'SUBJECT DISCONTINUATION', '54', '6.1.1', 'Adverse Event', '54', '6.1.2', 'Intercurrent Illness', '54', '6.1.3', 'Noncompliance', '54', '6.1.4', 'Refusal of Investigational Product Administration', '55', '6.1.5', 'Withdrawal of Consent', '55', '6.2', 'PREMATURE STUDY OR SITE TERMINATION', '55', '7.0', 'DATA COLLECTION AND PROCESSING AND STATISTICAL ANALYSIS', '57', '7.1', 'DATA COLLECTION AND PROCESSING', '57', '7.2', 'STATISTICAL ANALYSIS', '58', '7.2.1', 'General Overview', '58', '7.2.2', 'Sample Size', '58', '7.2.3', 'Exposure Analysis', '59', '7.2.4', 'Efficacy Analysis', '59', '7.2.5', 'Safety Analysis', '60', '7.2.6', 'Interim Analysis', '60', '7.2.7', 'Handling of Missing Data', '60', '7.3', 'INFORMED CONSENT AND AUTHORIZATION FOR USE AND DISCLOSURE OF', 'PROTECTED HEALTH INFORMATION', '61', '7.4', 'STUDY DOCUMENTATION', '61', '7.4.1', 'Investigator Information', '61', '7.4.2', \"Investigator's Study Files\", '61', '7.4.3', 'Case Report Forms and Source Documentation', '62', '7.4.4', 'Retention of Study Documents', '62', '7.5', 'CONFIDENTIALITY', '62', '7.5.1', 'Data', '62', '7.5.2', 'Subject Anonymity', '63', '7.6', 'PROTOCOL COMPLIANCE', '63', '7.7', 'STUDY MONITOR FUNCTIONS AND RESPONSIBILITY', '64', '7.8', 'GENERAL INFORMATION', '64', 'Page 13']\n\n###\n\n", "completion": "END"}